Welcome to the international HTA database

Showing [24901 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2004	Technology Assessment Unit of the McGill University Health Centre (MUHC)	The gastric banding procedure: an evaluation
2006	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Should the McGill University Health Centre use safety devices to reduce needlestick injuries associated with intravascular infusions?
2004	Technology Assessment Unit of the McGill University Health Centre (MUHC)	The use of matrix coils in the treatment of cerebro-vascular aneurysms
2006	Technology Assessment Unit of the McGill University Health Centre (MUHC)	The use of mitoxantrone in the treatment of patients with multiple sclerosis: report update
2006	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Testing for HER2 positive breast cancer: a cost-effectiveness analysis
2007	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Wait times at the MUHC. No: 3 fracture management.
2008	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Wait times at the MUHC. No: 4 Diagnostic imaging revisited. Adult hospitals of the MUHC.
2008	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Adoption of liquid-based cytology: technological evaluation
2008	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Impact of TAU reports
2017	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Plerixafor as first-line choice for stem cell mobilization in non-Hodgkin's lymphoma and multiple myeloma patients
2012	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Drotrecogin alfa (Activated) in severe sepsis: a systematic review of observational studies (Update of Report 29)
2012	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Video capsule endoscopy for obscure GI bleeding and Crohn's disease (Update of Report 7)
2012	Technology Assessment Unit of the McGill University Health Centre (MUHC)	532 nm KTP laser for vocal fold surgery
2012	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of serum procalcitonin levels in treatment decisions for adult patients in the intensive care unit
2012	Technology Assessment Unit of the McGill University Health Centre (MUHC)	The impact of reports of The Technology Assessment Unit of the McGill University Health Centre
2012	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Hyaluronic acid fat graft myringoplasty or Epidisk Tympanoplasty (ET)
2016	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Radiofrequency ablation for the treatment of Barrett's esophagus with high-grade and lowgrade dysplasia: an update
2015	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Single-dose intraoperative radiotherapy using Intrabeam® for early-stage breast cancer: an update
2016	Technology Assessment Unit of the McGill University Health Centre (MUHC)	A mini-health technology assessment of Linear and Radial Endobronchial Ultrasound (EBUS) and Electromagnetic Navigation Bronchoscopy (ENB) in the diagnosis and staging of lung cancer in adults
2016	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Cardiac resynchronization therapy in heart failure
2016	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of biventricular pacing in atrioventricular heart block
2017	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of extracorporeal membrane oxygenation for cardiac life support in adult subjects
2011	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Fiducial markers for improving treatment margins in radiotherapy for prostate cancer
2011	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin
2010	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Efficacy and cost-effectiveness of a gentamicin-loaded collagen sponge as an adjuvant antibiotic prophylaxis for colorectal surgery
2010	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Efficacy, safety and cost of ultrafiltration for the management of acute decompensated heart failure.
2010	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Negative Pressure Wound Therapy (NPWT) Update to Report 19
2005	Technology Assessment Unit of the McGill University Health Centre (MUHC)	The use of probiotics in the prevention and treatment of clostridium difficile diarrhea
2014	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Islet transplantation in patients with Type 1 Diabetes Mellitus
2014	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Excimer laser atherectomy for uncrossable coronary lesions and improperly deployed coronary stents
2003	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of the implantable cardiac defibrillator (ICD) at the McGill University Health Centre (MUHC)
2003	Technology Assessment Unit of the McGill University Health Centre (MUHC)	The use of self-expanding metallic stents in the palliation of dysphagia in patients with malignant esophageal strictures
2003	Technology Assessment Unit of the McGill University Health Centre (MUHC)	An evaluation of drug eluting (coated) stents for percutaneous coronary interventions: what should their role be at the McGill University Health Centre (MUHC)?
2007	Technology Assessment Unit of the McGill University Health Centre (MUHC)	The use of image-free computer-assisted systems in total knee replacement surgeries
2012	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Evaluation of acellular dermal matrix for breast reconstruction: an update
2007	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Drotrecogin alfa (activated) in severe sepsis
2012	Technology Assessment Unit of the McGill University Health Centre (MUHC)	The hybrid operating room. Should one be available for cardiovascular-thoracic procedures in the MUHC? A brief report
2012	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Single-dose intraoperative radiotherapy using Intrabeam® for early-stage breast cancer: a health technology assessment
2007	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Pulsatile machine perfusion compared to cold storage in kidney preservation
2005	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Vacuum-assisted wound closure therapy (V.A.C (R))
2005	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Intraoperative neurophysiological monitoring during spinal surgery
2005	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Cerebral microdialysis as a tool for neuromonitoring following traumatic brain injury
2005	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Botulinum toxin A for the treatment of refractory chronic anal fissures and internal anal sphincter achalasia in pediatric patients
2025	The Danish Health Technology Council (DHTC)	[Assessment of endovascular aortic repair (EVAR)]
2025	The Danish Health Technology Council (DHTC)	[Assessment of percutaneous vertebroplasty (PVP) for compression fractures]
2025	The Danish Health Technology Council (DHTC)	[Assessment of Merlin Assay for diagnosis of malignant melanoma]
2025	The Danish Health Technology Council (DHTC)	[Assessment of supervised gait training]
2025	The Danish Health Technology Council (DHTC)	[Assessment of SelfBack App for lower back pain]
2025	The Danish Health Technology Council (DHTC)	[Assessment of HAL-assisted TUR-BT]
2025	The Danish Health Technology Council (DHTC)	[Assessment of point-of-care tests for use at home for elderly patients]
2025	The Danish Health Technology Council (DHTC)	[Assessment of forearm fractures in children]
2025	The Danish Health Technology Council (DHTC)	[Assessment of treatment of knee pain]
2025	The Danish Health Technology Council (DHTC)	[The use of point of care tests (POCT) for elderly patients at home]
2025	The Danish Health Technology Council (DHTC)	[Analysis report on the management of persistent symptoms following meniscal injury]
2025	The Danish Health Technology Council (DHTC)	[Evaluation report concerning the SelfBack app for the treatment of non-specific low back pain]
2025	The Danish Health Technology Council (DHTC)	[Evaluation report concerning endovascular treatment of abdominal aortic aneurysms without rupture]
2025	The Danish Health Technology Council (DHTC)	[Evaluation report concerning HAL-Guided transurethral resection of bladder tumors in adult patients with suspected non-muscle-invasive bladder cancer]
2024	The Danish Health Technology Council (DHTC)	[Comparative health technology assessment of treatment modalities for obstructive sleep apnea: clinical effectiveness, patient perspectives, organizational and economic implications]
2025	The Danish Health Technology Council (DHTC)	[Evaluation report concerning supervised walking exercise for patients with intermittent claudication]
2024	The Danish Health Technology Council (DHTC)	[Assessment of domiciliary non-invasive ventilation for patients with chronic obstructive pulmonary disease]
2023	The Danish Health Technology Council (DHTC)	[Assessment concerning glucose monitoring for the treatment of adult patients with type 1 diabetes]
2023	The Danish Health Technology Council (DHTC)	[Use of artificial intelligence as clinical decision-support in colonoscopy for the diagnosis of neoplastic disease]
2024	The Danish Health Technology Council (DHTC)	[Guided, internet-based cognitive behavioral therapy for the treatment of adults with mild or moderate depression]
2023	The Danish Health Technology Council (DHTC)	[Assessment of pocket-sized handheld ultrasound devices for point-of-care examination of patients in emergency departments]
2023	The Danish Health Technology Council (DHTC)	[High-tech hospital beds for use in intensive and neurological wards]
2024	The Danish Health Technology Council (DHTC)	[Assessment of non-surgical treatment of distal radius fractures in patients older than 65 years]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Amikacin (Mycobacterium avium complex pulmonary infections)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Atidarsagen autotemcel (metachromatic leukodystrophy with biallelic mutation in the ARSA gene)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Autologous anti-CD19-transduced CD3+ cells (mantle cell lymphoma, pretreated patients)]
2021	The Federal Joint Committee (G-BA)	[Pharamceutical Directive/Annex XII: Avapritinib (gastrointestinal stromal tumours)]
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Axicabtagene ciloleucel (PMBCL)]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Bedaquiline (new therapeutic indication: multi-drug-resistant pulmonary tuberculosis, 12 to < 18 years)]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Birch Bark Extract (treatment of wounds associated with epidermolysis bullosa (6 months and older))]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Efgartigimod alfa (Myasthenia Gravis, AChR-antibody+)]
2024	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Sirolimus (facial angiofibroma associated with tuberous sclerosis complex, ≥ 6 years)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cabozantinib (reassessment after the deadline: thyroid carcinoma)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Brentuximab Vedotin (reassessment after the deadline: systemic anaplastic large cell lymphoma; first-line; combination with Cyclophosphamide, Doxorubicin, and Prednisone)]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Fenfluramine (Dravet syndrome, ≥ 2 years)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ixazomib (reassessment after the deadline: multiple myeloma, at least 1 prior therapy, combination with lenalidomide and dexamethasone)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Delamanid (repeal of the exemption: pulmonary multi-drug resistant tuberculosis, ≥ 10 kg)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cerliponase Alfa - reassessment after the deadline (type 2 neuronal ceroid lipofuscinosis)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Mosunetuzumab (follicular lymphoma, after ≥ 2 prior therapies)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Setmelanotide (obesity and control of hunger, POMC, PCSK1 or LEPR-deficiency obesity, ≥ 6 years)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Polatuzumab Vedotin (new therapeutic indication: diffuse large B-cell lymphoma (DLBCL), combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP))]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Satralizumab (neuromyelitis optica spectrum disorders, anti-aquaporin-4IgG seropositive, ≥ 12 years)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (new therapeutic indication: follicular lymphoma, pretreated patients)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Axicabtagene Ciloleucel (reassessment after the deadline: (diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Voxelotor (haemolytic anaemia in sickle cell disease, monotherapy or combination with hydroxycarbamide, ≥ 12 years)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Avapritinib (new therapeutic indication: systemic mastocytosis, after at least 1 prior therapy)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tebentafusp (uveal melanoma, HLA-A*02:01-positive)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Glucarpidase (reduction of toxic plasma methotrexate concentrations; aged 28 days and older)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Idebenone (reassessment after the deadline: Leber's Hereditary Optic Neuropathy)]
2024	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Epcoritamab (diffuse large B-cell lymphoma, after ≥ 2 prior therapies)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Voretigene Neparvovec (reassessment after the deadline: inherited retinal dystrophy)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Somatrogon (growth disturbance due to growth hormone deficiency, ≥ 3 to < 18 years]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ciltacabtagene autoleucel (relapsing/ refractory multiple myeloma, after at least 3 prior therapies)]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Belantamab mafodotin (reassessment after the deadline: multiple myeloma, at least 4 prior therapies, monotherapy)]
2016	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ataluren (expiry of the deadline)]
2024	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Bedaquiline (reassessment after the deadline: pulmonary multidrug-resistant tuberculosis)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Idecabtagen vicleucel (multiple myeloma, at least 3 prior therapies)]